MedTrace Logo

Combined Effects of Withania Somnifera & Syzgium Cumini on Hyperlipidemia

NCT07578857 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2026-05-11

No results posted yet for this study

Summary

Withania somnifera and Syzygium cumini are known for their potential therapeutic effects, particularly in managing lipid disorders. This study was aimed to provide valuable insights into their separate and synergistic effect of Withania somnifera (Ashwagandha) and Syzygium cumini (Jamun) on hyperlipidemic patients. The study included 60 patients, equally divided into four groups. Pre- and post-treatment assessments were conducted over 3 months. Each group recieved different treatment. Data was analyzed using SPSS version 21 through paired sample t-test. The findings of the research showed that Withania somnifera showed significant improvement in improving lipid profile and associated factors and concluded that the combination may be an effective and safe approach for managing hyperlipidaemia due to its beneficial impact on lipid profile.

Conditions

  • Hyperlipidemias

Interventions

DIETARY_SUPPLEMENT

Group C (treatment group 2)

In this intervention, participants were instructed to take Syzgium cumini (500mg) twice a day (BD).

COMBINATION_PRODUCT

Group D (treatment group 3)

In this intervention, participants were instructed to take both Withania somnifera and Syzgium cumini (1000 mg) once a day (QD).

DRUG

Atorvastatin 10mg

In this intervention, participants were instructed to take their usual medication for hyperlipidemia they were taking before.

DIETARY_SUPPLEMENT

Group B (treatment group 1)

In this intervention, participants were instructed to take Withania somnifera (500mg) twice a day (BD).

Sponsors & Collaborators

  • Riphah International University

    lead OTHER

Principal Investigators

  • Prof Dr. Muhammad Imran Hussain · Rashid Latif Khan University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
25 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-05-24
Primary Completion
2023-10-10
Completion
2023-10-25

Countries

  • Pakistan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07578857 on ClinicalTrials.gov